©2024 Stanford Medicine
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
Trial ID: NCT02572167
Purpose
The purpose of this study is to assess the safety profile and antitumor activity of
brentuximab vedotin administered in combination with nivolumab in patients with relapsed or
refractory Hodgkin lymphoma (HL)
Official Title
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Stanford Investigator(s)
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology
Eligibility
Inclusion Criteria:
- Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
chemotherapy for the treatment of classical Hodgkin lymphoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Previously treated with brentuximab vedotin, immune-oncology agents, or received an
allogeneic or autologous stem cell transplant
- Documented history of a cerebral vascular event
- History of another invasive malignancy that has not been in remission for at least 3
years
- History of progressive multifocal leukoencephalopathy (PML)
Intervention(s):
drug: brentuximab vedotin
drug: nivolumab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061